A Case-Control Study to Investigate Serological Correlates of Clinical Failure of 23-Valent Pneumococcal Polysaccharide Vaccine in HIV-1–infected Ugandan Adults.
Abstract
We have investigated the association between the concentration of anti–polysaccharide pneumococcal capsule–specific (anti‐PS) immunoglobulin G and the killing activity, in serum, in invasive pneumococcal disease (IPD) events and response to 23‐valent polysaccharide vaccine in human immunodeficiency virus (HIV)–infected Ugandans. Case patients with IPD had lower concentrations of anti‐PS IgG before and after vaccination and before the IPD event (PP=0.08), and for 23F, it was detected in 11% of case patients versus 40% of control subjects (P=0.02). Thus, absolute concentration of anti‐PS IgG and an attenuated response to polysaccharide are associated with risk of IPD in HIV‐infected adults.
Citation
Journal of Infectious Diseases (2004) 190(4) pp. 707-712 [DOI:10.1086/421911]